My laboratory studies various aspects of cardiovascular pathobiology and therapeutics. We are currently supported by the National Heart, Lung and Blood Institute and are particularly interested in disorders associated with diabetes, menopause, hypertension and heart failure. We use a combination of molecular, biochemical and cellular techniques in conjunction with animal models. Current areas of emphasis include:

1. Novel Therapeutic Approach for Hypertension: The increased incidence of cardiovascular morbidity following menopause is associated with the development of hypertension and cardiovascular remodeling. Our recent studies have identified unique estrogen-dependent and independent actions of the G protein-coupled estrogen receptor 1 (GPER, aka GPR30) in intracellular signaling and function of cardiovascular tissues. We are investigating the applicability of several peptides that we have developed based on these actions in the management of hypertension and cardiovascular remodeling.
2. Novel Mechanisms of Myocardial Autophagy: Autophagy (self-eating) is a normal process whereby tissues catabolize unnecessary components to maintain homeostasis and produce energy for tissue functions. Autophagy is important in myocardial adaptation to hypertrophic and ischemic stimuli and abnormal autophagy promotes the development of heart failure. We are investigating the mechanisms of action whereby several G protein-coupled receptors regulate myocardial autophagy. Efforts are also being made to develop new approaches to monitor in real-time indicators of autophagy.
3. Development of Novel Reagents To Reduce Blood Glucose in Type II Diabetes: Type 2 diabetes (T2D) is a major health problem worldwide. A main pathological feature of T2D is the reduction in function of pancreatic beta cells, leading to reduced production of insulin. We have identified novel mechanisms that can be exploited to promote the secretion of insulin from these cells while protecting their other functions. This project will use a combination of molecular, cellular, biochemical approaches, coupled with studies in animal models and human pancreatic tissues to develop and characterize mechanistically novel therapeutic agents that promote the production of insulin from pancreatic beta cells and test their effects in animal models of T2D.